Application of Massively Parallel Sequencing to Genetic Diagnosis in Multiplex Families with Idiopathic Sensorineural Hearing Impairment

Chen-Chi Wu1,2, Yin-Hung Lin1,3, Ying-Chang Lu1, Pei-Jer Chen4,5, Wei-Shiung Yang2,4,5,6, Chuan-Jen Hsu1*, Pei-Lung Chen2,5,6,7*

1 Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan, 2 Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, 3 Graduate Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, 4 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, 5 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 6 Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan, 7 Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan

Abstract

Despite the clinical utility of genetic diagnosis to address idiopathic sensorineural hearing impairment (SNHI), the current strategy for screening mutations via Sanger sequencing suffers from the limitation that only a limited number of DNA fragments associated with common deafness mutations can be genotyped. Consequently, a definitive genetic diagnosis cannot be achieved in many families with discernible family history. To investigate the diagnostic utility of massively parallel sequencing (MPS), we applied the MPS technique to 12 multiplex families with idiopathic SNHI in which common deafness mutations had previously been ruled out. NimbleGen sequence capture array was designed to target all protein coding sequences (CDSs) and 100 bp of the flanking sequence of 80 common deafness genes. We performed MPS on the Illumina HiSeq2000, and applied BWA, SAMtools, Picard, GATK, Variant Tools, ANNOVAR, and IGV for bioinformatics analyses. Initial data filtering with allele frequencies (<5% in the 1000 Genomes Project and 5400 NHLBI exomes) and PolyPhen2/SIFT scores (>0.95) prioritized 5 indels (insertions/deletions) and 36 missense variants in the 12 multiplex families. After further validation by Sanger sequencing, segregation pattern, and evolutionary conservation of amino acid residues, we identified 4 variants in 4 different genes, which might lead to SNHI in 4 families compatible with autosomal dominant inheritance. These included GJB2 p.R75Q, MYO7A p.T381M, KCNQ4 p.S680F, and MYH9 p.E1256K. Among them, KCNQ4 p.S680F and MYH9 p.E1256K were novel. In conclusion, MPS allows genetic diagnosis in multiplex families with idiopathic SNHI by detecting mutations in relatively uncommon deafness genes.

Introduction

Hearing loss is a common sensory disorder. Approximately 1 in 500 newborns are affected with bilateral moderate or more severe sensorineural hearing impairment (SNHI). Before the age of 5, the prevalence increases to 2.7 per 1,000, and during adolescence, to 3.5 per 1,000 [1]. It has been revealed that more than 50% of children with SNHI have attributable genetic factors [2]. As such, genetic testing is a powerful tool for a precise genetic diagnosis in hearing-impaired children. In addition, this diagnostic approach provides clues concerning the pathogenesis of hearing impairment, and allows for an accurate prognosis [3,4], facilitates genetic counseling [5], prevents further hearing loss [6], and might help to design novel strategies for future treatment.

However, the genetic heterogeneity of hereditary hearing impairment remains a major obstacle to obtaining molecular diagnoses in the majority of cases. To date, more than 100 genes have been identified to cause nonsyndromic hereditary hearing impairment (The Hereditary Hearing Loss Homepage, http://hereditaryhearingloss.org/) [7]. For example, in Taiwan, although mutations in certain genes such as GJB2 (or Cx26) (Gene ID: 2706), SLC26A4 (or PDS) (Gene ID: 5172), and the mitochondrial 12SrRNA gene (MTRNR1) (Gene ID: 4549) have been shown to be much more prevalent than other genes, a definitive diagnosis by direct sequencing of these coding regions could only be established in approximately 1/3 patients with idiopathic SNHI [8] and 1/4 patients with cochlear implantation [4], respectively. It is likely that there are other, relatively uncommon, genetic mutations that contribute to SNHI in some of the remaining families, especially those with many affected members (i.e., multiplex families).

Recently, the development of massively parallel sequencing (MPS), also known as next-generation sequencing (NGS), which generates millions of DNA sequence reads in parallel during a single experimental run, offers a potential solution to approach
hereditary disorders with genetic heterogeneity such as retinitis pigmentosa [9], breast cancer [10], cardiomyopathy [11], and hereditary hearing impairment [12,13]. To investigate the diagnostic utility of MPS, we applied the MPS technique to a cohort composed of 12 families with idiopathic SNHI in which common deafness mutations had been ruled out as the cause.

Materials and Methods

Family Recruitment and Phenotype Characterization

Twelve multiplex families with idiopathic nonsyndromic SNHI, including 10 families compatible with autosomal dominant inheritance and 2 families compatible with autosomal recessive inheritance (Figure S1), were enrolled in the present study. All 12 families were Han Chinese from Taiwan in ethnicity. Prior mutation screening using the SNaPshot multiplex assays, which targeted 20 common deafness-associated mutations in the Han Chinese population of Taiwan [14], did not detect mutations in these 12 families. For the proband and affected family members, comprehensive family history and past medical records were obtained, and physical examination, neurological examination, audiological results, and temporal bone imaging results were obtained and analyzed. Audiological results were assessed and characterized in terms of 2 parameters: hearing levels and audiogram shapes [15]. The hearing level of the better ear, calculated by a 4-tone average (0.5, 1, 2, and 4 kHz), was labeled as mild (20–40 dBHL), moderate (41–70 dBHL), severe (71–95 dBHL), or profound (>95 dBHL) hearing loss (GEN-DEAF: http://audiology.unife.it/www.gendeaf.org/index.html). Temporal bone imaging results were obtained using high-resolution computed tomography and/or magnetic resonance imaging, and inner ear malformations (IEMs) were identified and determined according to the criteria in the literature [15]. Written informed consent for participation in the project was obtained from the subjects, and all procedures were approved by the Research Ethics Committee of the National Taiwan University Hospital.

Target Enrichment, Massively Parallel Sequencing and Variant Calling

Figure 1 depicts the major criteria for identification of causative variants in the affected families, including target enrichment, massively parallel sequencing, variant calling, and data filtering. Genomic DNA (gDNA) was extracted from the probands of the 12 families and submitted to Otogenetics Corporation (Norcross, GA, USA) for exome capture and sequencing. Briefly, gDNA was

Table 1. Number of Variants Detected in the Probands of the 12 Families.

| Proband | Inheritance | SNP | Private indels | Total | Nonsense | Missense | Splice junctions | Frameshift | Total |
|---------|-------------|-----|----------------|-------|----------|----------|-----------------|-----------|-------|
| DE2087  | ADNSHL      | 296 | 4              | 300   | 1        | 3        | 1               | 0         | 5     |
| DE2180  | ADNSHL      | 284 | 4              | 288   | 2        | 5        | 1               | 0         | 8     |
| DE2548  | ADNSHL      | 298 | 4              | 302   | 1        | 4        | 1               | 0         | 6     |
| DE2616  | ADNSHL      | 278 | 4              | 282   | 1        | 3        | 0               | 1         | 5     |
| DE2624  | ADNSHL      | 98  | 3              | 101   | 1        | 2        | 1               | 0         | 4     |
| DE2675  | ADNSHL      | 138 | 4              | 142   | 1        | 7        | 2               | 0         | 10    |
| DE2721  | ADNSHL      | 182 | 4              | 186   | 2        | 10       | 0               | 0         | 12    |
| DE2737  | ARNSHL      | 284 | 4              | 288   | 2        | 3        | 0               | 0         | 5     |
| DE2827  | ARNSHL      | 109 | 3              | 112   | 1        | 4        | 0               | 0         | 5     |
| DE2939  | ARNSHL      | 367 | 8              | 375   | 2        | 0        | 1               | 0         | 3     |
| DE3050  | ADNSHL      | 171 | 3              | 174   | 1        | 10       | 0               | 1         | 12    |
| DE3281  | ADNSHL      | 148 | 2              | 150   | 1        | 6        | 0               | 0         | 7     |

SNP, single nucleotide polymorphism; ADNSHL, autosomal dominant nonsyndromic hearing loss; ARNSHL, autosomal recessive nonsyndromic hearing loss.

doi:10.1371/journal.pone.0057369.t001
subjected to agarose gel and O.D. ratio tests to confirm its purity and concentration prior to Covaris fragmentation (Covaris, Inc., Woburn, MA, USA). Fragmented gDNAs were tested for size distribution and concentration using the Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA) and Nanodrop (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Illumina libraries were generated from fragmented gDNA (only after the gDNA passed the quality control checks) using NEBNext reagents (New England Biolabs, Ipswich, MA, USA; catalog #: E6040), and the resulting libraries were subjected to target enrichment using custom probes targeting the Human Deafness Gene DA panel (Otogenetics Corporation) following the manufacturer’s instructions. The libraries were first tested for enrichment by qPCR and for size distribution and concentration using the Agilent Bioanalyzer 2100. The samples were then sequenced on an Illumina HiSeq2000 that generated paired-end reads of 100 nucleotides.

We aligned the raw sequencing data to the latest reference human genome (Feb. 2009, GRCh37/hg19) using the BWA software (version 0.5.9) [16]. We used SAMTools (version 0.1.18) [17] and Picard (version 1.54) (http://picard.sourceforge.net) to perform the necessary data conversion, sorting, and indexing. The main variant calling process, for both indels (insertion/deletions) and single nucleotide variants, was operated by using the GATK software package (version 1.2-59-gd74367c1) [18,19]. We applied Variant Tools (version 1.0.2) to select and analyze the variants and single nucleotide variants, was operated by using the GATK main variant calling process, for both indels (insertion/deletions) and single nucleotide variants, was operated by using the GATK software package (version 1.2-59-gd74367c1) [18,19]. We applied Variant Tools (version 1.0.2) to select and analyze the variants and single nucleotide variants, was operated by using the GATK main variant calling process, for both indels (insertion/deletions) and single nucleotide variants, was operated by using the GATK software package [18,19].

We used ANNOVAR (version 2012-03-08) was used to appropriately annotate the genetic variants [21]. This included gene annotation, amino acid change annotation, SIFT scores [22], PolyPhen2 scores [23], dbSNP identifiers, 1000 Genomes Project allele frequencies, and NHLBI-ESP 5400 exome project allele frequencies. We then used IGV (version 2.1.16) to view the mapping and annotation of sequences on a graphic interface [24,25].

### Data Filtering

After variant calling, we used ANNOVAR to annotate genetic variants, identify variants that are reported in dbSNP135, and check if variants have already been reported in the 1000 Genomes Project (Feb. 2012) or NHLBI-ESP 5400 exome project (all ethnicity). Only variants with allele frequencies <5% in both the 1000 Genomes Project and NHLBI-ESP 5400 exome project were selected. Among these variants, all frameshift and non-frameshift indel variants, nonsense variants, and splice site variants were included for further analysis. In contrast, for missense variants, PolyPhen2 and SIFT (http://sift.jcvi.org/) were used to assess the effect on the protein. SIFT prediction is based on the degree of conservation of amino acid residues in multiple alignment information. The amino acid substitution is predicted damaging if the score is >0.95, and tolerated if the score is <0.95. Accordingly, missense variants with a score <0.95 in PolyPhen2 or SIFT were excluded. Variants meeting the aforementioned criteria were then subjected to Sanger sequencing to confirm the nucleotide change; segregation pattern were obtained to determine if the variant co-segregated with the hearing impairment phenotype in the pedigrees, and the evolutionary conservation of amino acid residues was assessed. Known variants present in databases (http://deafnessvariationdatabase.org/) and published in the literature as disease-causing were regarded as pathogenic mutations. The mutated gene identified in each family was classified as autosomal dominant or autosomal recessive according to the Hereditary Hearing Loss Homepage (http://hereditaryhearingloss.org), and was then correlated to the inheritance pattern in each family. Allele frequencies of the

### Table 2: The Variants Identified in the 6 Families Compatible with Autosomal Dominant Inheritance.

| Proband | Inheritance | Genomic Reference | Reference Coordinates | Reads | Total Variant | Gene | cDNA | Protein | SIFT | PolyPhen2 | Criteria |
|---------|-------------|-------------------|-----------------------|-------|--------------|------|------|---------|------|----------|---------|
| DE284   | Autosomal dominant | Chr13:20763497 | 1            | 120   | 251          | GJB2 | c.224G>A | p.R75Q  | 0.999 | 0.999 | DE284   |
| DE2675  | Autosomal dominant | Chr1:41304146 | T          | 97    | 233          | KCNQ4 | c.1877C>T | p.S680F | 0.98  | 0.999 | DE2675  |
| DE2721  | Autosomal dominant | Chr22:36690209 | C> T     | 78    | 201          | MYH9 | c.3766G>A | p.E1256K | 1     | 1       | DE2721  |
| DE2827  | Autosomal dominant | Chr1:35227362 | G> C     | 120   | 222          | MYO7A | c.507C>G | p.C169W | 0.028 | 0.028 | DE2827  |
| DE3050  | Autosomal dominant | Chr11:76871270 | T> C     | 32    | 73           | DE3050 | c.1142C>T | p.T381M | 0.028 | 0.028 | DE3050  |
| DE3281  | Autosomal dominant | Chr1:35227362 | G> C     | 155   | 305          | GJB4 | c.507C>G | p.C169W | 0.028 | 0.028 | DE3281  |
variants detected were also verified in a panel of 100 controls with normal hearing of the same ethnicity.

Results

Target Enrichment and Massively Parallel Sequencing

DNA libraries were created from the probands of the 12 multiplex families with SNHI (Table 1). As shown in Supplementary Material, Table S1, the Human Deafness DA1 Panel was designed to enrich for all coding sequences (CDSs) and splicing sites of 80 confirmed human deafness genes. This covered 1,253 exons with a total coding region of 193,634 bp. The enriched targets then were submitted to MPS using the Illumina HiSeq2000 and the paired-end protocol with a length of 100 bp. The average coverage was 490 folds. 99.3% of sequences had coverage greater than 30 folds, 99% greater than 50 folds, and 95.3% greater than 100 folds.

Data Filtering and Identification of Causative Variants

Initial data filtering with allele frequencies and PolyPhen2/SIFT scores prioritized 5 indels and 36 missense variants in the 12 multiplex families. After further validation by Sanger sequencing, segregation pattern, and assessment of evolutionary conservation of amino acid residues, we identified 5 variants in 5 different genes, which might have led to SNHI in 6 of the families compatible with autosomal dominant inheritance. These included GJB2 p.R75Q, MYO7A (GeneID 4647) p.T381M, KCNJQ4 (GeneID 9132) p.S680F, MIH9 (GeneID 4627) p.E1256K, and GJB4 (GeneID 127534) p.C169W (Table 2).

Known Causative Variants: GJB2 p.R75Q and MYO7A p.T381M

We identified 2 known causative variants, GJB2 p.R75Q (c.224G>A) and MYO7A p.T381M (c.1142C>T), in Family DE2624 and Family DE3050, respectively (Figure 2). Variant reads of GJB2 p.R75Q were 48% (120/251) of total reads in the proband of Family DE2624, suggesting heterozygosity of the allele (Table 2). p.R75Q has been associated to both autosomal dominant nonsyndromic hearing loss (ADNSHL) [26] and autosomal dominant SNHI with palmoplantar keratoderma [27]. The proband of Family DE2624 was a 5-year-old girl with profound hearing loss (Figure 2E) and normal temporal bone imaging results. Palmoplantar keratoderma was not observed in the affected members of Family DE2624, thus indicating that the phenotype associated with GJB2 p.R75Q in this family was nonsyndromic hearing loss.

In the proband of Family DE3050, variant reads of MYO7A p.T381M were 56% (41/73) of the total reads, suggesting
heterozygosity of the allele (Table 2). Heterozygosity for MYO7A p.T381M has been documented in 3 unrelated patients with nonsyndromic SNHI from Taiwan [28], and co-segregated with the phenotype of hearing impairment in the pedigree of Family DE3050 (Figure 2B). The proband of Family DE3050 was a 31-year-old man with progressive, moderate SNHI (Figure 2F) and no inner ear malformations (IEM) on temporal bone imaging studies. None of the affected members in Family DE3050 exhibited retinitis pigmentosa.

**Novel Causative Variants: KCNQ4 p.S680F and MYH9 p.E1256K**

In Family DE2675, we identified the p.S680F (c.1877C>T) variant in the KCNQ4 gene, which has not been reported previously (Figure 3A). The pathogenicity of KCNQ4 p.S680F was supported by its high SIFT (0.98) and PolyPhen2 (0.99) scores, as well as its absence in the 5400 NHLBI exomes, 1000 Genomes, and the 100 normal hearing controls of the present study (Table 2). Furthermore, heterozygosity for p.S680F co-segregated with the phenotype of hearing impairment in the pedigree (Figure 3B), and the amino acid residue p.S680 was evolutionarily conserved (Figure 3C). The proband of Family DE2675 was a 7-year-old girl with mild low-tone hearing loss, and her mother’s hearing loss began at adolescence and gradually deteriorated to mild SNHI until her current age (Figure 3D). Both exhibited normal temporal bone imaging results. By contrast, the elder sister (III-1) of the proband who did not segregate the p.S680F variant demonstrated a normal audiogram.

In Family DE2721, we identified the p.E1256K (c.3766G>A) variant in the MYH9 gene, which has not been reported previously (Figure 4A). The pathogenicity of MYH9 p.E1256K was supported by its high SIFT (1.00) and PolyPhen2 (1.00) scores, as well as its absence in 5400 NHLBI exomes, 1000 Genomes, and the 100 normal hearing controls (Table 2). In addition, heterozygosity for p.E1256K co-segregated with the phenotype of hearing impairment in the pedigree (Figure 4B), and the amino acid residue p.E1256 was evolutionarily conserved (Figure 4C). The proband of Family DE2721 was a 57-year-old woman with profound SNHI that had progressed since 10 years of age (Figure 4D). One of her sons had segregated the MYH9 p.E1256K variant and also exhibited progressive SNHI of moderate severity. The result of the temporal imaging study performed in the proband was normal. Comprehensive renal, hematological, and ophthalmological studies in the proband revealed normal results, and her affected son (III-2) also showed normal laboratory findings on complete blood count and serum renal profiles. Hematologic and renal disorders were ruled out in other affected members of Family DE2721 by history.

**Probable Non-causative Variant: GJB4 p.C169W**

In Family DE2827 and Family DE3281, we identified the p.C169W (c.507C>G) variant in the GJB4 gene (Figure 5A). In both Family DE2827 and Family DE3281, heterozygosity for GJB4 p.C169W co-segregated with the hearing impairment phenotype in the pedigree (Figure 5B and 5C), except for case I-1 of Family DE2827, which exhibited normal hearing that corresponded to his age. The proband of Family DE2827 was a...
44-year-old woman with progressive severe SNHI (Figure 5E, upper panel), whereas the proband of Family DE3281 was a 50-year-old woman with progressive SNHI of moderate severity (Figure 5E, lower panel). Both probands exhibited normal temporal bone imaging results. The SIFT and PolyPhen2 scores of $GJB4_{p.C169W}$ were 1.00 (Table 2). The amino acid residue p.C169 was evolutionarily conserved (Figure 5D), and heterozygosity for the nonsense mutation at this amino acid residue (i.e., p.C169X) has been related to nonsyndromic SNHI in a Han Chinese family from Taiwan [29]. However, the allele frequencies of $GJB4_{p.C169W}$ were as high as 2.8% and 3.0% in 5400 NHLBI exomes and 1000 Genomes, respectively. Among the 100 normal hearing controls, we also identified 6 carriers with $GJB4_{p.C169W}$, revealing an allele frequency of 3.0% (6/200 chromosomes). Therefore, probably $GJB4_{p.C169W}$ is a non-pathogenic variant.

**Discussion**

In the present study, we applied MPS to 12 multiplex families with idiopathic SNHI. We identified 5 variants in 5 different genes, which might have led to SNHI in 6 families compatible with autosomal dominant inheritance, including $GJB2_{p.R75Q}$, $MYO7A_{p.T381M}$, $KCNQ4_{p.S680F}$, $MYH9_{p.E1256K}$, and $GJB4_{p.C169W}$ (Figure 6). Four variants were classified as pathogenic variants, including 2 known variants ($GJB2_{p.R75Q}$ and $MYO7A_{p.T381M}$) and 2 novel variants ($KCNQ4_{p.S680F}$ and $MYH9_{p.E1256K}$). The remaining variant, $GJB4_{p.C169W}$, was classified as a probable non-causative variant, as its allele frequency was as high as ~3% in the general population.

Among the deafness-associated genes identified thus far, mutations in $GJB2$ are the most common cause of monogenic hearing impairment worldwide. $GJB2$ encodes a gap junction protein, connexin 26, and the major function of connexin 26 in the inner ear is to regulate potassium recycling [30]. To date, 2 mutations at the p.R75 amino acid residue of connexin 26 have been related to autosomal dominant SNHI with or without palmoplantar keratoderma: p.R75W [31,32] and p.R75Q [26,27]. $GJB2_{p.R75Q}$ was identified in 1 Turkish and 2 French families, with the severity of hearing loss ranging from mild to profound SNHI in the affected individuals [26,27]. We failed to detect p.R75Q in our first pass of mutation screening using the SNaPshot multiplex assays, as p.R75Q was not included in the screening panels because it had never been detected in our previous genetic epidemiological survey [8].

Another known causative variant identified in the present study is $MI07A_{p.T381M}$. The human $MI07A$ gene consists of 48 coding exons, and encodes the unconventional myosin MYO7A with 2,215 amino acids [33]. Different $MI07A$ mutations might lead to a wide variety of phenotypes with different inheritance patterns, ranging from Usher syndrome type 1B [34], autosomal recessive nonsyndromic hearing loss (ARNSHL) (DFNB2) [33,35], to ADNSHL (DFNA11) [36]. $MI07A_{p.T381M}$ was identified in 1 Turkish and 2 Chinese families, with the severity of hearing loss ranging from mild to profound SNHI in the affected individuals [26,27]. We failed to detect p.R75Q in our first pass of mutation screening using the SNaPshot multiplex assays, as p.R75Q was not included in the screening panels because it had never been detected in our previous genetic epidemiological survey [8].
Together with the results of this study, it is likely that MYO7A p.T381M is associated with ADNSHL.

In addition to the 2 known causative variants, we identified 2 novel variants, i.e., KCNQ4 p.S680F and MYH9 p.E1256K, in 2 families, respectively. The KCNQ4 gene, which encodes the voltage-gated potassium channel KCNQ4 in outer hair cells, has been identified at the ADNSHL DFNA2 locus on the human chromosome 1p34 [37]. To date, 11 missense mutations, 1 nonsense mutation, and 2 deletion mutations of the KCNQ4 gene have been documented in DFNA2 patients with various clinical phenotypes (The Deafness Variation Database: http://deafnessvariationdatabase.org) [38]. KCNQ4 p.S680F is located at the cytoplasmic C terminus and contributes to progressive SNHI in the affected members of Family DE2675. The MYH9 gene encodes myosin IIA heavy chain, which is involved in actomyosin-microtubule crosstalk, cell motility, and maintenance of cell shape [39]. Defects in MYH9 have been associated with ADNSHL DFNA17 [40], as well as a plethora of autosomal dominant syndromes with hematologic and/or renal manifestations in addition to progressive SNHI [41]. As none of the affected members in Family DE2721 demonstrated symptoms other than SNHI, the p.E1256K variant might lead to nonsyndromic SNHI only.

The GJB4 p.C169W variant was detected in 2 other autosomal dominant families. GJB4 p.C169W fulfilled most criteria used for data filtering in the present study, including allele frequency <5% in the general population, high PolyPhen2 and SIFT scores, and evolutionary conservation of p.C169 amino acid residues. It is important to note, that the allele frequency of GJB4 p.C169W is approximately 3% in the general population, which is, to some extent, higher than the convention definition of a mutation, i.e., the allele frequency of a mutation should be less than 1% [42]. It has been demonstrated that the allele frequencies of several common deafness mutations are higher than 1% in the general population, e.g., GJB2 p.V37I (10% in some East Asian general populations) [43,44], c.235delC (1.5% in the Chinese general population) [45], and c.35delG (~1.3% in the European general population) [46]. However, all these mutations are recessive. As such, it is unlikely that GJB4 p.C169W leads to ADNSHL given its high allele frequency in the population. However, there might be hypothetical possibility that this variant indeed contributes to SNHI through “autosomal dominant but low penetrance” or “oligogenic” inheritance pattern; we therefore still presented the results in this paper for the sake of completeness.

In addition to the 2 families with GJB4 p.C169W, we were not able to obtain a genetic diagnosis in the other 4 ADNSHL families and the 2 ARNSHL families using the current MPS panel (Figure 6), although many affected members strongly suggest a genetic cause of deafness in these families. As the MPS diagnostic panel of the present study only targeted the coding sequences and...
splicing sites of known deafness genes, genetic defects in regulatory elements, e.g., un-translated regions (UTRs), enhancers, promoters, and intronic splicing regulatory elements, could not be examined. Large deletions or insertions of 100 bp, as well as inversions, might also be missed because of the short average read length of the Illumina platform used in our MPS diagnostic panel. Another possibility is that deafness in these families might be caused by mutations in genes other than the 80 known deafness genes targeted in the present study. For the latter possibility, whole exome sequencing might be helpful in identifying novel deafness genes in the future.

The MPS technology, via targeted sequencing of whole exomes [47] or specific chromosomal regions confined by linkage analysis and homozygosity mapping [48], has been proven to be a powerful tool for discovering novel deafness genes (for a detailed review, please refer to [49]). In addition to gene discovery, the

Table 3. Summary of the 5 Series Investigating the Diagnostic Utility of MPS.

| Reference          | Targeted regions                                      | Subjects enrolled for MPS                                                                 | Main results                                                                 |
|--------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Shearer et al.     | 54 known deafness genes in humans; exons and 50 bp    | 3 positive controls with mutations detected previously by Sanger sequencing and 6 patients | Causative mutations were confirmed in the 3 positive controls. Pathogenic mutations were identified in 5 of the 6 idiopathic SNHL patients, including 3 novel mutations. Genetic diagnosis remained elusive in an ADNSHL patient. |
|                    | flanking introns                                      | with idiopathic SNHL. The 6 idiopathic SNHL patients included 4 with ADNSHL and 2 with ARNSHL. [ethnicity: NA] |                                                                              |
| Brownstein et al.  | 246 genes responsible for deafness in humans (85 genes) and mice (161 genes); exons and 40 bp flanking introns | 11 unrelated families with idiopathic SNHL, including 2 with ADNSHL and 9 with ARNSHL. [ethnicity: 5 Israeli Jewish and 6 Palestinian Arab] | Pathogenic mutations were identified in 2 ADNSHL and 4 ARNSHL families, including 4 novel mutations. Genetic diagnosis could be achieved in all 5 Jewish families, but in only 1 Palestinian family. |
| Tang et al.        | 5 selected known deafness genes in humans; exons and 50 bp flanking introns | 10 positive controls previously detected to have mutations in GJB2 by Sanger sequencing. [ethnicity: NA] | Causative GJB2 mutations were confirmed in the positive controls, and additional variants in other selected targeted genes were identified. |
| De Keulenaer et al.| 15 ARNSHL genes in humans; exons and most of the UTRs | 1 positive control and 3 ARNSHL families (4 individuals). [ethnicity: the 3 ARNSHL families included 2 Iranian and 1 Turkish] | The causative mutation was confirmed in the positive control. Pathogenic mutations were identified in 2 ARNSHL families, including 2 novel mutations. |
| This study         | 80 known deafness genes in humans; exons and 100 bp    | 12 multiplex families with idiopathic SNHL, including 10 with ADNSHL and 2 with ARNSHL. [ethnicity: all Han Chinese] | Causative variants were identified in 4 ADNSHL families, including 2 novel variants. |
|                    | flanking introns                                      |                                                                                           |                                                                              |

MPS, massively parallel sequencing; SNHL, sensorineural hearing impairment; ADNSHL, autosomal dominant nonsyndromic hearing loss; ARNSHL, autosomal recessive nonsyndromic hearing loss; NA, not available; UTR, untranslated region.

doi:10.1371/journal.pone.0057369.t003
diagnostic utility of MPS in addressing genetically heterogeneous nonsyndromic hearing loss has also been examined in several studies (Table 3). Shearer et al. performed targeted capture of 54 known deafness genes in 9 individuals, including 3 positive controls with mutations detected previously and 6 patients with idiopathic SNHL. Causative mutations were confirmed in all 3 positive controls, and genetic diagnosis was achieved in 5 of the 6 idiopathic SNHL patients [12]. Brownstein et al. developed a targeted capture pool composed of 246 deafness genes (85 human and 161 mouse genes), and applied it to 11 unrelated families with idiopathic SNHL, including 2 with ADNSHL and 9 with ARNSHL. They established genetic diagnosis in 2 ADNSHL and 4 ARNSHL families, and identified 4 novel mutations. Interestingly, a genetic diagnosis was made in all 5 Jewish families, and 4 ARNSHL families, and identified 4 novel mutations.

For the difference in the diagnostic yield between populations, as but in only 1 of the 6 Palestinian families. A possible explanation is that MPS accurately facilitated the genetic diagnosis in a certain proportion of idiopathic SNHI patients [12]. Brownstein et al. developed a targeted capture pool composed of 400 deafness genes, including 2 with ADNSHL and 9 with ARNSHL. They established genetic diagnosis in 2 ADNSHL and 4 ARNSHL families, and identified 4 novel mutations. Interestingly, a genetic diagnosis was made in all 5 Jewish families, but in only 1 of the 6 Palestinian families. A possible explanation for the difference in the diagnostic yield between populations, as proposed by the authors, is that inherited hearing loss in the Palestinian population is more heterogeneous than in the Israeli population because of historical marriage patterns [13]. Tang et al. selected 5 known deafness genes to test the diagnostic efficacy of MPS in 10 positive controls previously identified to have GJB2 mutations by Sanger sequencing. They successfully confirmed the causative mutations in all positive controls and detected additional variants in the other selected genes [50]. De Keulenaer et al. screened 15 ARNSHL genes in 1 positive control and 3 ARNSHL families with MPS and identified a pathogenic mutation in 2 ARNSHL families of Iranian ancestry [51]. In the present study, we performed targeted capture of 80 known deafness genes in 10 ADNSHL and 2 ARNSHL families and identified causative variants in 4 ADNSHL families. In summary, MPS accurately detected causative mutations in the positive controls in these series and facilitated the genetic diagnosis in a certain proportion of idiopathic SNHI families. However, the diagnostic yield of MPS may depend on several factors, including the number of targeted genes, the MPS platform used, the inheritance pattern, and the ethnic background of the families tested.

In conclusion, by applying the MPS diagnostic panel targeting 80 deafness genes to 12 multiplex Han Chinese families with idiopathic nonsyndromic SNHL, we identified 4 variants in 4 different genes, which might have led to SNHL in 4 families compatible with autosomal dominant inheritance, including GJB2 p.R75Q, MYO7A p.T301M, KCNQ4 p.S680F, and MYH9 p.E1256K. Among them, KCNQ4 p.S680F and MYH9 p.E1256K are novel variants. Thus, MPS enables genetic diagnosis in multiplex families with idiopathic SNHL by detecting mutations in relatively uncommon deafness genes.

Supporting Information

Figure S1 The pedigrees of the 12 multiplex families recruited in the present study. Families compatible with autosomal dominant inheritance and autosomal recessive inheritance are marked with AD and AR, respectively. Arrows indicate the probands.

(TIF)

Table S1 The 80 known human deafness genes included in DA1.

(DOC)

Author Contributions

Conceived and designed the experiments: CCW CJH PJC PLC. Performed the experiments: YHL YCL. Analyzed the data: PLC YHL. Contributed reagents/materials/analysis tools: YHL YCL. Wrote the paper: CCW WSY PJC PLC.

References

1. Morton CC, Nance WE (2006) Newborn hearing screening—a silent revolution. N Engl J Med 354: 2151–2164.
2. Smith RJ, Bale JF Jr, White KR (2005) Sensorineural hearing loss in children. Lancet 365: 679–680.
3. Wu CC, Lee YC, Chen PJ, Hsu CJ (2008) Predominance of genetic diagnosis and imaging results as predictors in determining the speech perception performance outcome after cochlear implantation in children. Arch Pediatr Adolesc Med 162: 269–276.
4. Wu CC, Liu TC, Wang SH, Hsu CJ, Wu CM (2011) Genetic characteristics in children with cochlear implants and the corresponding auditory performance. Laryngoscope 121: 1287–1293.
5. Wu CC, Lin SY, Su YN, Fang MY, Chen SU, et al. (2010) Preimplantation genetic diagnosis (embryo screening) for enlarged vestibular aqueduct due to SLC26A4 mutation. Audiol Neurootol 15: 311–317.
6. Hamsaaki K, Rando RR (1997) Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry 36: 12233–12238.
7. Höger N, Smith RJ, Van Camp G (2008) Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res 601: 189–196.
8. Wu CC, Chen PJ, Chiu YH, Lu YC, Wu MC, et al. (2008) Prospective mutation screening of three common deafness genes in a large Taiwanese Cohort with idiopathic bilateral sensorineural hearing impairment reveals a difference in the results between families from hospitals and those from rehabilitation facilities. Audiol Neurootol 13: 172–181.
9. Simpson DA, Clark GR, Alexander S, Silvestri G, Willoughby CE (2011) Molecular diagnosis for heterogeneous genetic diseases with targeted high-throughput DNA sequencing applied to retinitis pigmentosa. J Med Genet 48: 121–122.
10. Morgan JE, Carr IM, Sheridan E, Chu CE, Hayward B, et al. (2010) Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat 31: 484–491.
11. Meder B, Haas J, Keller A, Heidi C, Just S, et al. (2011) Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 4: 110–122.
12. Shearer AD, Dehaja AP, Hildebrand MS, Taylor KR, Gurrola J Jr, et al. (2010) Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A 107: 21104–21109.
13. Brownstein Z, Friedman LM, Shahin H, Orton-Karni V, Kol N, et al. (2011) Targeted genomic capture and massively parallel sequencing to identify genes for hereditary hearing loss in middle eastern families. Genome Biol 12: R99.
14. Wu CC, Li YC, Chen PJ, Liu YL, Hsu WL, et al. (2009) Application of SNAPSHOT multiplex assays for simultaneous multigene mutation screening in patients with idiopathic sensorineural hearing impairment. Laryngoscope 119: 2411–2416.
15. Wu CC, Chen YS, Chen PJ, Hsu CJ (2005) Common clinical features of children with enlarged vestibular aqueduct and Mondini dysplasia. Laryngoscope 115: 132–137.
16. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079.
18. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297–1303.
19. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491–498.
20. San Lucas FA, Wang G, Scheet P, Peng B (2012) Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics 28: 421–422.
21. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from next-generation DNA sequencing data. Nat Genet 42: 60–65.
22. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073–1081.
23. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 240–240.
24. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24–26.
25. Thorvaldsdottir H, Robinson JT, Mesirov JP (2012) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform.

26. Feldmann D, Denoyelle F, Blons H, Lyonnet S, Loundon N, et al. (2005) The GJB2 mutation R75Q can cause nonsyndromic hearing loss DFNA3 or hereditary palmoplantar keratoderma with deafness. Am J Med Genet A 137: 225–227.

27. Uyguner O, Tukel T, Baykal C, Eris H, Emiroglu M, et al. (2002) The novel R75Q mutation in the GJB2 gene causes autosomal dominant hearing loss and palmoplantar keratoderma in a Turkish family. Clin Genet 62: 306–309.

28. Su MC, Yang YJ, Su CC, Hsin CH, Li SY (2009) Identification of novel variants in the Myosin VIIA gene of patients with nonsyndromic hearing loss from Taiwan. Int J Pediatr Otorhinolaryngol 73: 811–815.

29. Yang YJ, Wang WH, Lin YC, Weng HH, Yang JT, et al. (2010) Prospective variants screening of connexin genes in children with hearing impairment: genotype/phenotype correlation. Hum Genet 128: 303–313.

30. Kikuchi T, Kimura RS, Paul DL, Takasaka T, Adams JC (2000) Gap junction systems in the mammalian cochlea. Brain Res Brain Res Rev 32: 163–166.

31. Richard G, White TW, Smith LE, Bailey RA, Compton JG, et al. (1998) Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Hum Genet 103: 395–399.

32. Janecke AR, Nekahm D, Loffler J, Hirst-Stadlmann A, Muller T, et al. (2001) De novo mutation of the connexin 26 gene associated with dominant non-syndromic sensorineural hearing loss. Hum Genet 108: 269–270.

33. Weil D, Kussel P, Blanchard S, Levy G, Levi-Acobas F, et al. (1997) The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA gene. Nat Genet 16: 191–193.

34. Weil D, Blanchard S, Kaplan J, Guilford P, Gibson F, et al. (1995) Defective myosin VIA gene responsible for Usher syndrome type 1B. Nature 374: 60–61.

35. Liu XZ, Walsh J, Mburu P, Kendrick-Jones J, Cope MJ, et al. (1997) Mutations in the myosin VIA gene cause nonsyndromic recessive deafness. Nat Genet 16: 191–193.

36. Liu XZ, Walsh J, Tamagawa Y, Kitamura K, Nishizawa M, et al. (1997) Autosomal dominant non-syndromic deafness caused by a mutation in the myosin VIA gene. Nat Genet 17: 268–269.

37. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, et al. (1999) KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96: 437–446.

38. Nie L (2008) KCNQ4 mutations associated with nonsyndromic progressive sensorineural hearing loss. Curr Opin Otolaryngol Head Neck Surg 16: 441–444.

39. Even-Ram S, Yamada KM (2007) O’Mice and Men: Relevance of Cellular and Molecular Characterization of Myosin IIA to MYH9-Related Human Disease. Cell Adhesion & Migration 1: 152–155.

40. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, et al. (2000) Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet 67: 1121–1128.

41. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, et al. (2003) MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82: 203–215.

42. Harris H, Hopkinson DA, Luffman J (1968) Enzyme diversity in human populations. Ann N Y Acad Sci 131: 232–242.

43. Hwa HL, Ko TM, Hsu CJ, Huang CH, Chiang YL, et al. (2003) Mutation spectrum of the connexin 26 (GJB2) gene in Taiwanese patients with prelingual deafness. Genet Med 5: 161–165.

44. Watanasirichaigoon D, Limwongse C, Jariengprasert C, Ynachtsmanan PT, Tocharoenthanaphol C, et al. (2004) High prevalence of V37I genetic variant in the connexin-26 (GJB2) gene among non-syndromic hearing-impaired and control Thai individuals. Clin Genet 66: 452–460.

45. Dai P, Yu F, Han B, Liu X, Wang G, et al. (2005) GJB2 mutation spectrum in 2,003 Chinese patients with nonsyndromic hearing impairment. J Transl Med 7: 26.

46. Van Eyken P, Cachero L, Fransen E, Topsakal V, Hendrickx JJ, et al. (2007) The contribution of GJB2 (Connexin 26) 35delG to age-related hearing impairment and noise-induced hearing loss. Otol Neurotol 28: 970–975.

47. Rehman AU, Morel RJ, Belysanteva IA, Khan SY, Boger ET, et al. (2010) Targeted capture and next-generation sequencing identifies C890T5, encoding taperin, as the mutated gene in nonsyndromic deafness DFNB79. Am J Hum Genet 86: 378–388.

48. Walsh T, Shahin H, Elkan-Miller V, Lee MK, Thornton AM, et al. (2010) Whole exome sequencing and homozygosity mapping identify mutation in the cell polarity protein GPSM2 as the cause of nonsyndromic hearing loss DFNB82. Am J Hum Genet 87: 90–94.

49. Brownstein Z, Bohnker Y, Avraham KB (2012) High-throughput sequencing to decipher the genetic heterogeneity of deafness. Genome Biol 13: 245.

50. Tang W, Qian D, Ahmad S, Mattox D, Todd NW, et al. (2012) A low-cost exon capture method suitable for large-scale screening of genetic deafness by the massively-parallel sequencing approach. Genet Test Mol Biomarkers 16: 536–542.

51. De Keulenaer S, Hellemans J, Lefever S, Renard JP, De Schrijver J, et al. (2012) MPS Genetic Diagnosis for Deafness.